{
    "title": "111_s1383",
    "content": "The Act may be cited as the \"Dextromethorphan Abuse Reduction Act of 2009\". Congress finds that cough medicines containing dextromethorphan, when abused at high doses, can lead to dangerous effects such as hallucinations, rapid heart rate, and seizures. The accessibility and low cost of dextromethorphan have contributed to increased abuse, especially among teenagers. Prolonged high-dose use can result in psychological dependence on the drug. The abuse of dextromethorphan can lead to impaired judgment, injury, or death. Approximately 1,700,000 teenagers abused over-the-counter cough medicines in 2008. The FDA considers dextromethorphan abuse a serious issue, warning of potential adverse effects like brain damage, seizures, and irregular heartbeats. Retailers have implemented age restrictions on purchasing cough medicines with dextromethorphan. Prevention through education campaigns is crucial in addressing the rise in dextromethorphan abuse among teenagers. Manufacturers have added warnings on packaging of cough and cold medicines to alert parents about the dangers of medicine abuse. Sales of products containing dextromethorphan are subject to civil penalties under the Controlled Substances Act. Sales of products containing dextromethorphan to individuals under 18 years of age is prohibited, including online sales. Failure to check identification is considered knowledge of the buyer's age. Sales of products containing dextromethorphan to individuals under 18 years of age is prohibited, including online sales. An affirmative defense is allowed if the seller checked the purchaser's ID and reasonably concluded they were at least 18 years old. This does not apply to sales with a valid prescription. The Attorney General must create regulations for Internet sales within 180 days of enactment. The Attorney General can enforce civil penalties for violations of selling products containing dextromethorphan to individuals under 18 years of age, with penalties increasing for repeat offenses. The Attorney General can enforce civil penalties for violations of selling products containing dextromethorphan to individuals under 18 years of age. Violations by employees or agents are considered violations by the person as well. Retailers can mitigate penalties by implementing employee training programs or other compliance measures. The term 'identification card' refers to a card with a photo and date of birth issued by a State or Federal Government, or meeting specific federal regulations. A 'retailer' includes grocery stores, drug stores, and other entities selling products. The Senate emphasizes the importance of manufacturers including warnings about dextromethorphan abuse on product packages and retailers implementing safeguards against theft. The Director of National Drug Control Policy will provide grants to eligible entities for a nationwide education campaign on preventing prescription and nonprescription drug abuse among individuals under 18 and their parents. Eligible entities must be not-for-profit organizations with national experience and capabilities. The eligible entity for the nationwide education campaign on drug abuse prevention must have specific expertise in conducting education campaigns, experience working with various groups, conducted research for the campaign, generated news media coverage, and secured pro bono media time and space. The nationwide education campaign on drug abuse prevention requires an entity with expertise in education campaigns, experience with various groups, research, news media coverage, and pro bono media time. $4,000,000 is authorized for fiscal years 2010-2012 for this purpose. Grant funds should supplement, not supplant, other available funds. Grants are also available for education, training, and technical assistance to community coalitions. The Director of National Drug Control Policy will award a grant for education, training, and technical assistance to community coalitions nationwide on drug abuse prevention. $1,500,000 is authorized for each fiscal year from 2010 to 2012 for this purpose. Grant funds must supplement other available funds. Under this subsection, funds are to supplement, not replace, Federal and non-Federal funds for activities described. Definitions for terms like \"Administrator\" and \"drug\" are provided. An eligible entity is defined as an organization applying for a grant. The organization applying for a grant must have previously received a grant under the Drug-Free Communities Act of 1997 and must have documented rates of drug abuse above national averages. The term \"nonprescription drug\" is defined in the Federal Food, Drug, and Cosmetic Act. The Food, Drug, and Cosmetic Act defines prescription drugs and authorizes grants for community-wide drug abuse prevention programs. Eligible entities can apply for enhancement grants to implement strategies for preventing abuse of prescription and nonprescription drugs. An eligible entity applying for a grant must submit a detailed plan to address drug abuse. Grant funds are to be used for implementing a community-wide strategy to combat drug abuse. Grant terms for the program include a maximum 4-year period and funding not exceeding $100,000 per year. The funds are meant to supplement existing resources, not replace them, and evaluation requirements are in place similar to the Drug-Free Communities Act of 1997. Administrative expenses are capped at 6 percent. Authorization of appropriations is set at $4,000,000 annually for fiscal years 2010 through 2012. Data collection should include monitoring trends in drug abuse, including prescription and nonprescription drugs. Amendments to the Controlled Substances Act involve removing and redesignating certain paragraphs. The table of contents for the Comprehensive Drug Abuse Prevention and Control Act of 1970 is amended by redesignating paragraph (3) as paragraph (2). \"Sec. 424. Civil penalties for certain dextromethorphan sales.\""
}